European Psychiatry - Volume 41 - April 2017

148 / 916

S144 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169
The next aim was to compare profiles of cognitive impairment in
both groups of patients.
The last aim was to find out a relationship between cognitive per-
formance and severity of depressive episode during the acute state
of illness.
Methods We have used neuropsychological test battery
(Auditory–Verbal Learning Test, Rey-Osterrieth Complex Fig-
ure Test, Logical Memory, Digit span test, Trail making test, Verbal
Fluency Test, Block Design and Benton Visual Retention Test) for
the evaluation of the cognitive functions in patients with severe
depressive episode with psychotic symptoms (n = 5) and patients
with major depressive disorder (n = 8).
Results We found cognitive impairment in all examined domains
in both groups of patients.
More profound cognitive impairment was found in patients with
severe depressive episode with psychotic symptoms, particu-
larly in visual memory, visuo-constructive abilities, speed of
cognitive processing and executive functions. We found no cor-
relation between cognitive performance and severity of depressive
episodes.
Conclusions Our findings suggest a strong correlation between
psychotic symptoms in depression and cognitive performance.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0115
Maternal depressive symptom
trajectories and psychosocial
functioning in young adults: A 27-year
longitudinal study
I. Luoma ∗, M. Korhonen , R. Salmelin
1 Tampere University Hospital, Child Psychiatry, Tampere, Finland
2 Helsinki University Hospital, Child Psychiatry, Helsinki, Finland
3 University of Tampere, School of Health Sciences, Tampere, Finland
∗ Corresponding author.
Introduction Maternal depression is a well-known risk factor for
child development. Longitudinal studies extending frompregnancy
to adulthood, however, are rare.
Objectives The aim of the study was to investigate whether
maternal high depressive symptom trajectories (chronic or inter-
mittent depressive symptom patterns) from pregnancy to the
adolescence of the children predict lower adaptive functioning
or higher levels of emotional or behavioural symptoms in young
adults.
Methods The sample comprised 329 first-time mothers from
maternity centres in Tampere, Finland. Maternal depressive symp-
toms were assessed with the Edinburgh Postnatal Depression Scale
(EPDS) antenatally and at two months, six months, 4–5 years,
8–9 years and 16–17 years after delivery. A model including four
symptom trajectories (very low, low-stable, high-stable and inter-
mittent) was selected to describe the symptom patterns over time.
Adaptive functioning and problems of the children (n = 144) were
assessed by the Adult Self Report forms (Achenbach & Rescorla) at
the age of 27 years.
Results High maternal depressive symptom trajectories did not
predict self-reported lower adaptive functioning of the children in
adulthood. However, children of mothers with chronic or inter-
mittent depressive symptom patterns reported higher levels of
internalising problems as well as symptoms of depression and anx-
iety in young adulthood than the children of mothers with very low
or low stable symptom patterns.
Conclusions Highmaternal depressive symptom trajectories pre-
dict higher levels of emotional symptoms of children in young
adulthood. The mechanisms of intergenerational transmission are
important topics for further research.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0116
Quetiapine XR as add-on to
antidepressants in
treatment-resistant late-life major
depression
O. Vasiliu ∗, D. Vasile , D.G. Vasiliu , A. Andreea Filareta ,
F. Vasile
1 “Dr. Carol Davila” Central Military Hospital, Psychiatry, Bucharest,
Romania
2 Coltea Clinical Hospital, Internal Medicine, Bucharest, Romania
3 University of Medicine and Pharmacy Titu Maiorescu, General
Medicine, Bucharest, Romania
∗ Corresponding author.
Objective To assess the efficacy and tolerability of quetiapine as
add-on to antidepressant agents in treatment-resistant late-life
major depression.
Methods A group of 15 patients, 8 male and 7 female, mean
age 68.2, evaluated in our department for clinical symptoms that
made possible a DSM 5 diagnosis of major depressive disorder,
were initiated on quetiapine XR, flexible daily dose 50–300mg QD.
All patients were on treatment with an antidepressant–either a
selective serotonin reuptake inhibitor (SSRI) (n = 10), or venlafax-
ine (n = 5)–for at least 6 weeks and presented no improvement
during current treatment administered at therapeutic doses.
Patients were assessed using Montgomery Asberg Depression Rat-
ing Scale (MADRS), Clinical Global Impression–Severity (CGI-S),
Global Assessment of Functioning (GAF), and Columbia Suicide
Severity Rating Scale (C-SSRS) every 4 weeks for 3 months.
Results After 12 weeks, patients had a mean improvement in
MADRS score of 45.7 ±2.3%, with a final mean MADRS score of 13.5
(P < 0.01). No variations were registered depending on the specific
SSRI or venlafaxine concomitant treatment. Quetiapine XR mean
daily dose administered during the studywas 125mg. C-SSRS didn’t
registered significant variations in suicidal ideation or behavior
throughout the trial. Overall GAF score increased with 22.1 points,
and CGI-S decreasedwith a mean of 1.5 points at week 12 (P < 0.01).
Tolerability of add-on quetiapine was very good, no serious adverse
event being reported.
Conclusions Quetiapine was efficient and well tolerated in late-
life resistant major depression, as add-on to SSRIs or venlafaxine,
during the 12 weeks of the trial.
Disclosure of interest The presenting author was speaker for Bris-
tol Myers Squibb and Servier, and participated in clinical research
funded by Janssen Cilag, Astra Zeneca, Eli Lilly, Sanofi Aventis,
Schering Plough, Organon, Bioline Rx, Forenap, Wyeth, Otsuka
Pharmaceuticals, Dainippon Sumitomo.
EW0117
The clinical course of depression:
Chronicity is the rule rather than the
exception
J. Verhoeven ∗, J. Verduijn , Y. Milaneschi , A. Beekman ,
B. Penninx
VU University Medical Center, Psychiatry, Amsterdam, The
Netherlands
∗ Corresponding author.
Introduction Major depressive disorder (MDD) is often consid-
ered an episodic disorder. However, literaturemight underestimate
the chronicity of MDD since results depend on follow-up dura-